EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 6b

Ensembl ID : ENSDARG00000058736
Gene Symbol: GABRA6B
4 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Delta

Ensembl ID : ENSDARG00000059763
Gene Symbol: GABRD
5 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Gamma 2

Ensembl ID : ENSDARG00000053665
Gene Symbol: GABRG2
4 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 4

Ensembl ID : ENSDARG00000013389
Gene Symbol: GABRA4
4 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1a

Ensembl ID : ENSDARG00000018967
Gene Symbol: GABBR1A
5 Cross references
203 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1b

Ensembl ID : ENSDARG00000016667
Gene Symbol: GABBR1B
17 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSDARG00000061042
Gene Symbol: GABBR2
17 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit A

Ensembl ID : ENSDARG00000079586
Gene Symbol: GABRB2A
4 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta3 Subunit

Ensembl ID : ENSDARG00000023771
Gene Symbol: GABRB3
4 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma1 Subunit

Ensembl ID : ENSDARG00000101995
Gene Symbol: GABRG1
5 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSDARG00000100032
Gene Symbol: GABRB2
4 Enzyme and pathways 3 Cross references
145 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSDARG00000025478
Gene Symbol: GIPR
7 Enzyme and pathways 5 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).